Novartis AG (NVSEF) stock
NVSEFOTCPharmaceutical PreparationsFiscal year ends December 31Also trades as NVS
$146.46+2.56 (+1.78%)
Close on Oct 19, 2026Market cap $279.46BP/E 20.5Yield –
Novartis operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
For fiscal 2025 it was $19.14B, up 8.7% from the year before. Over ten years it grew 4.9% a year on average. The highest annual figure on record is $19.14B in fiscal 2025.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $19.14B | +8.7% |
| FY2024 | Dec 31, 2024 | $17.62B | +21.9% |
| FY2023 | Dec 31, 2023 | $14.46B | +1.6% |
| FY2022 | Dec 31, 2022 | $14.24B | -5.5% |
| FY2021 | Dec 31, 2021 | $15.07B | +10.4% |
| FY2020 | Dec 31, 2020 | $13.65B | +0.2% |
| FY2019 | Dec 31, 2019 | $13.63B | -4.5% |
| FY2018 | Dec 31, 2018 | $14.27B | +13.1% |
| FY2017 | Dec 31, 2017 | $12.62B | +10.0% |
| FY2016 | Dec 31, 2016 | $11.48B | -3.5% |
| FY2015 | Dec 31, 2015 | $11.90B | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $5.88B | +56.6% |
| Q2 FY2025 | Jun 30, 2025 | $6.66B | +61.3% |
| Q2 FY2024 | Jun 30, 2024 | $4.88B | +23.1% |
| Q2 FY2023 | Jun 30, 2023 | $3.58B | +14.9% |
| Q2 FY2022 | Jun 30, 2022 | $3.76B | -4.7% |
| Q2 FY2021 | Jun 30, 2021 | $4.13B | – |
| Q2 FY2020 | Jun 30, 2020 | $3.96B | – |
| Q2 FY2019 | Jun 30, 2019 | $3.11B | – |
| Q2 FY2018 | Jun 30, 2018 | $3.94B | – |
See a number that looks wrong?